Journal of Oncology / 2020 / Article / Tab 3

Review Article

EGFR Polymorphism and Survival of NSCLC Patients Treated with TKIs: A Systematic Review and Meta-Analysis

Table 3

EGFR genotype and survival (PFS and TTP) of NSCLC patients treated with TKIs.

dbSNP-IDVariant type, location, and/or consequenceAuthor, year (ref)Genotyping platform usedGenotypeNo. of patients (%)Progression-free survival (PFS) (95% CI)Time-to-progression (TTP) (95% CI)

rs11568315Intron variant, g.55020560_55020561AC[n]Giovannetti et al., 2010 [57]TaqMan assayBoth alleles ≤ 16CA30 (31.9)NA3.2 (0.7–5.7)b
At least 1 allele > 16CA64 (68.1)NA3.1 (2.4–3.8)b
Han et al., 2007 [55]PCR and fragment length analysisBoth alleles ≥ 38CA46 (53.5)NAReference
Both alleles ≤ 37CA40 (46.5)NA0.54 (0.34–0.88)a
Ichihara et al., 2007 [26]PCR and sequencingShort allele ≥ 19CA or the sum of alleles ≥ 39CA63 (64.3)ReferenceNA
Short allele < 19CA or the sum of alleles < 39CA35 (35.7)1.08 (0.63–1.86)aNA
Kim et al., 2017 [61]TaqMan assay and sequencingBoth alleles ≤ 16CA74 (28.0)ReferenceNA
At least 1 allele > 16CA188 (72.0)0.94 (0.71–1.25)aNA
Liu et al., 2008 [56]PCR-RFLPAt least 1 allele > 16CA59 (64.0)ReferenceNA
Both alleles ≤ 16CA33 (36.0)0.54 (0.33–0.88)aNA
Winther Larsen et al., 2014 [59]PCR-RFLP and capillary electrophoresisAny allele ≤ 16CA44 (71.0)0.39 (0.22–0.70)aNA
Both alleles > 16CA18 (29.0)ReferenceNA

rs2227983Missense variant, 1562G>A, R497KGiovannetti et al., 2010 [57]TaqMan assayGG or GA81 (88.0)NA3.3 (2.4–5.0)b
AA11 (12.0)NA3.1 (1.5–4.7)b
Liu et al., 2008 [56]PCR-RFLPAA43 (47.0)ReferenceNA
GG or GA49 (53.0)1.54 (0.98–2.42)aNA

rs2293347Synonimous variant, 181946C>T, D994DWinther-Larsen et al., 2015 [32]AS-PCR or PCR followed by sequencingCC252 (80.0)ReferenceNA
CT or TT64 (20.0)0.74 (0.55–0.99)aNA

rs7128295′ UTR variant, g.5031G>T, -216G>TGiovannetti et al., 2010 [57]TaqMan assayGG34 (36.2)NA3.2 (2.6–3.8)b
GT or TT60 (63.8)NA3.2 (0.8–5.7)b
Jung et al., 2012 [25]PCR-RFLP or PCR followed by sequencingGG63 (88.7)5.1 (2.7–7.5)bNA
GT8 (11.3)16.6 (5.8–27.5)bNA
Kim et al., 2017 [61]Taqman PCR and sequencingGG78 (32.0)ReferenceNA
GT or TT162 (68.0)0.78 (0.59–1.03)aNA
Winther-Larsen et al., 2015 [32]AS-PCR or PCR followed by sequencingGG134 (42.0)ReferenceNA
GT or TT182 (58.0)0.90 (0.70–1.14)aNA
Liu et al., 2008 [56]PCR-RFLPGG34 (37.0)ReferenceNA
GT or TT58 (63.0)0.62 (0.38–0.99)aNA
rs7128305′ UTR variant, g.5056A>C, -191C/AGiovannetti et al., 2010 [57]TaqMan assayCC78 (83.0)NA3.2 (2.5–3.9)b
CA or AA16 (17.0)NA3.2 (3.0–3.4)b
Kim et al., 2017 [61]Taqman PCR and sequencingCC195 (81.0)ReferenceNA
CA or AA45 (19.0)1.13 (0.8–1.58)aNA
Winther-Larsen et al., 2015 [32]AS-PCR or PCR followed by sequencingCC236 (75.0)ReferenceNA
CA or AA80 (25.0)1.15 (0.88–1.51)aNA
Liu et al., 2008 [56]PCR-RFLPCC81 (88.0)ReferenceNA
CA or AA11 (12.0)0.86 (0.40–1.85)aNA

aHazard ratio (HR); bMedian (months); NA–not available; in bold, significant result at the level <0.05.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.